Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Cibc World Markets Corp acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC.

stocks here >>>> Xeris Biopharma is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Aurinia Pharmaceuticals (AUPH), finished the last trading session 1.7% ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report). The company’s shares closed last Friday at $3.83.

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...

Xeris Biopharma Holdings ... is an industry leading US-based pharmaceutical company. For nearly 60 years, American Regent has been developing, manufacturing and supplying quality generic and ...

Conference call and webcast at 8:30am ET CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to... CHICAGO - Xeris ...